What one share of CNS Pharmaceuticals holds
Together, these therapeutic areas represent hundreds of billions of dollars in annual global pharmaceutical
CNS Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$7.71 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$6.21 |
| Cash and investments | $13.67 |
| Debt | $0.21 |
| Book value | $12.45 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$466.89 | $0.13 | −$537.90 | — | — |
| 2025 | — | −$35.75 | $0.04 | −$31.19 | — | $7.15 |
Common questions about CNS Pharmaceuticals
How much does one share of CNS Pharmaceuticals earn?
Over the last 12 months, CNS Pharmaceuticals lost $7.71 for each share.
Does CNS Pharmaceuticals pay a dividend?
CNS Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is CNS Pharmaceuticals’s book value per share?
CNS Pharmaceuticals’s book value is $12.45 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of CNS Pharmaceuticals have?
Each share of CNS Pharmaceuticals has $13.67 of cash and investments and $0.21 of debt, as of June 30, 2026.
What is CNS Pharmaceuticals’s free cash flow per share?
−$6.21 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.